A slightly higher-than-previous placebo response on the primary endpoint of two hours' freedom from headache did little to take the shine off top-line phase III migraine data disclosed by Colucid Pharmaceuticals Inc. with lasmiditan tablets in the trial known as SAMURAI. Read More

LONDON – Glaxosmithkline plc has reported statistically significant results in what it claims is the world's first real-world randomized control trial, the Salford lung study (SLS). Read More

Looking to mine more gold from its respiratory drug franchise, Astrazeneca plc offered up full data from the pivotal phase III trials of benralizumab at the European Respiratory Society (ERS) meeting in London, seeking to position the company's first biologic respiratory medicine as a key differentiator in the space. Read More

DUBLIN – A syndicate of European venture capital investors has followed its own money in a sizable third closing of Rigontec GmbH's series A round, adding €15 million (US$16.7 million) in new cash, which takes the final tally to €29.25 million. Read More

TOKYO – Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, will attempt to develop a vaccine to tackle the Zika virus with funding from the U.S. government worth up to $311 million. Read More

DUBLIN – DBV Technologies SA is extending its patch-based antigen delivery technology, which is currently undergoing a pivotal phase III trial in a food allergy indication, into its first vaccine study. Read More

HONG KONG – A new Japanese study of the effects of environmental and genetic influences on individual differences in proteomics and metabolomics has identified biomarkers for early disease prevention and diagnosis, through the identification and quantification of blood metabolites. Read More

In its third letter of the year, the FDA's Office of Prescription Drug Promotion (OPDP) came down on Celator Pharmaceuticals Inc. for promoting a promising but yet-to-be-approved cancer drug in an exhibit at the American Society for Clinical Oncology's (ASCO) annual meeting in June. Read More

C4X Discovery Holdings plc, of Manchester, U.K., raised £5 million (US$6.7 million) by placing approximately 4.9 million ordinary shares with current and new investors at 102 pence apiece. Read More

Spero Therapeutics LLC, of Cambridge, Mass., joined the ENABLE (European Gram-Negative Antibacterial Engine) project, which focuses on the development of promising early stage antimicrobial candidates to treat gram-negative infections. Read More

Basilea Pharmaceutica Ltd., of Basel, Switzerland, said the first patient was dosed in a phase I/IIa continuous infusion study with its tumor checkpoint controller, BAL101553, in patients with advanced solid cancers. Read More